Bioengineering – University of California, San Diego

[ graduate program | courses | faculty ]

STUDENT AFFAIRS 141 Powell-Focht Bioengineering Hall Warren College http://www.be.ucsd.edu

All courses, faculty listings, and curricular and degree requirements described herein are subject to change or deletion without notice. Updates may be found on the Academic Senate website: http://senate.ucsd.edu/catalog-copy/approved-updates/.

Bioengineering is an interdisciplinary major in which the principles and tools of traditional engineering fields, such as mechanical, materials, electrical, and chemical engineering, are applied to biomedical and biological problems. Engineering plays an increasingly important role in medicine in projects that range from basic research in physiology to advances in biotechnology and the improvement of health-care delivery. By its very nature, bioengineering is broad and requires a foundation in the engineering sciences as well as in physiology and other biological sciences.

The overall mission of the Department of Bioengineering is to improve health and quality of life by applying engineering principles to scientific discovery and technology innovation and to train future leaders in bioengineering through inspiring education and dedicated mentorship.

The educational objectives of the bioengineering program at UC San Diego are to produce graduates with a modern bioengineering education who will

At the undergraduate level, the department offers several four-year engineering majors, including a newly developed BS in Bioengineering: BioSystems. This major focuses on the interaction and integration of components in complex biological and engineering assemblages, and how the function and interactions of these components affect overall performance. The major draws on foundations of classical electrical and systems engineering, with biological applications at levels of the molecular and cellular to the physiological and whole organism, and provides an alternative to other bioengineering majors that emphasize mechanical, chemical, and computational approaches. The major prepares students for careers in the bioengineering industry, in research and development, and for further education in graduate, medical, and business schools.

One major leads to a BS in Bioengineering. This major prepares students for careers in the biomedical device industry and for further education in graduate school. Students completing the BS in Bioengineering have a broad preparation in traditional topics in engineering, allowing for a variety of career pathways. This program addresses the bioengineering topics of biomechanics, biotransport, bioinstrumentation, bioelectricity, biosystems, and biomaterials, and the complementary fields of systems and integrative physiology. Education in these areas allows application of bioengineering and other scientific principles to benefit human health by advancing methods for effective diagnosis and treatment of disease, e.g., through development of medical devices and technologies.

The department also offers a BS in Bioengineering: Biotechnology. This major prepares students for careers in the biotechnology industry and for further education in graduate school. The curriculum has a strong engineering foundation with emphasis on biochemical process applications. This program addresses the bioengineering topics of biochemistry, metabolism, kinetics, biotransport, biosystems, bioreactors, bioseparations, tissue engineering, and the complementary fields of cellular physiology. Education in these areas allows application of bioengineering and physicochemical principles to cellular and molecular biology, with the applications that benefit human health.

The department also offers a major leading to a BS in Bioengineering: Bioinformatics. Bioinformatics is the study of the structure and flow of information (genetic, metabolic, and regulatory) in living systems. The bioinformatics major emphasizes computation and model-based approaches to assembling, integrating, and interpreting biological information. This major has been developed by the Departments of Bioengineering, Chemistry and Biochemistry, Computer Science and Engineering, and the Division of Biological Sciences, and students may apply through any of these departments or the division. The major prepares students for careers in the pharmaceutical, biotechnology, and biomedical software industries, and for further studies in graduate or medical school.

The programs and curricula of the Department of Bioengineering emphasize education in the fundamentals of engineering sciences that form the common basis of all engineering subspecialties. Education with this emphasis is intended to provide students with an interdisciplinary engineering foundation for a career in which engineering practice may expand rapidly. In addition, elements of bioengineering design are incorporated at every level in the curricula. This is accomplished by integration of laboratory experimentation, computer applications, and exposure to real bioengineering problems throughout the program. In the Bioengineering, Bioengineering: Biotechnology, and Bioengineering: BioSystems majors, students also work in teams on a senior design project to design a solution to a multidisciplinary bioengineering problem suggested by professionals in bioengineering industry, academia, or medicine.

The Engineering Accreditation Commission of the Accreditation Board for Engineering and Technology (EAC/ABET) is an organization with a mission of serving the public through promotion and advancement of education in fields including engineering, and ABETs strategic plans include accreditation of educational programs and promotion of quality and innovation in education http://www.abet.org. At UC San Diego, Bioengineering, Bioengineering: Biotechnology, and Bioengineering: BioSystems have a relatively heavy emphasis on engineering, whereas Bioengineering: Bioinformatics has a relatively heavy emphasis on biological, chemical, and physical sciences. The Bioengineering and Bioengineering: Biotechnology programs are accredited by EAC/ABET, and ABET accreditation will be sought for the Bioengineering: BioSystems major. The Bioengineering: Bioinformatics program is not accredited by a Commission of ABET.

At the graduate level, specialized curricula lead to the MS, MEng (Master of Engineering), and PhD, as well as an integrated BS/MS. The department also offers a PhD in Bioinformatics. It is intended for students who have an interdisciplinary persuasion to work across computers, biology, medicine, and engineering. For further information on the degree, please e-mail bioinfo@ucsd.edu or go online to http://www.bioinformatics.ucsd.edu. The MEng is a terminal professional degree whereas the MS and PhD are research programs. (See section on masters degree programs.) The graduate programs are characterized by strong interdisciplinary relationships with the other engineering departments and Departments of Physics, Mathematics, Biology, Chemistry and Biochemistry, Medicine, and others, as well as with campus organizations such as the Institute of Engineering in Medicine, Institute for Mechanics and Materials, and the School of Medicine.

Specific course requirements for each of the majors are outlined in tables below. In addition to the required technical courses specifically indicated, a suggested scheduling of humanities and social science courses (HSS) is included in the curricula for students to use to meet college general-education requirements. To graduate, students must maintain an overall GPA of at least 2.0, and obtain at least a C grade in each course required for the major. All courses required for the major must be taken for a letter grade.

Deviations from the required programs of study must be approved by the Undergraduate Studies Committee prior to students taking alternative courses. In addition, students must obtain departmental approval of technical elective (TE) course selections prior to students taking the course. In the ABET-accredited programs, TE courses are restricted to those that meet ABET standards. Courses such as BENG 197 and 198 are encouraged, but do not count as upper-division technical electives. BENG 195, 196, and 199 can be used as technical electives under certain conditions. Policy information may be obtained from the Student Affairs Office.

Students with accelerated academic preparation at admission to the university may vary the scheduling of lower-division courses such as mathematics, physics, and chemistry, but must first consult the department. Most lower-division courses are offered more than once each year to permit students some flexibility in their program scheduling. However, most upper-division bioengineering courses are taught only once each year.

Deviations in the scheduling of upper-division bioengineering courses are strongly discouraged, as such changes usually lead to a delay in graduation.

The curricula shown in the tables below are consistent with the current scheduling of classes.

Minors are not offered in the Department of Bioengineering, and double major options are restricted. Students interested in double majors should consult the Student Affairs Office as early as possible.

For graduation, each student must satisfy general-education course requirements determined by the students college, as well as the major requirements determined by the department. The six colleges at UC San Diego require different general-education courses, and the number of such courses differs from one college to another. Each student should choose his or her college carefully, considering the special nature of the curriculum and the breadth of general education.

The bioengineering programs allow for humanities and social science (HSS) courses so that students can fulfill their college requirements. In the bioengineering ABET-accredited programs, students must develop a program that includes a total of at least forty units in the arts, humanities, and social sciences, not including subjects such as accounting, industrial management, finance, or personnel administration. It should be noted, however, that some colleges require more than the ten HSS courses indicated in the Bioengineering, Bioengineering: Biotechnology, Bioengineering: Bioinformatics, and Bioengineering: BioSystems curriculum tables. Accordingly, students in these colleges may take longer to graduate than the four years indicated in the schedule. Students must consult with their colleges to determine which HSS courses to take.

(ABET-Accredited Program)

1Chem 7L may be taken in any quarter within the first two years after completion of Chem 6B.

2BENG 1 may be taken in sophomore year.

3Ten HSS courses are listed here; individual college requirements may be higher.

4Recommended course, not required.

5Design elective (DE) courses must be selected from a two-quarter sequence, BENG 119AB, 126AB, 127AB, 128AB, 129AB, 139AB, 147AB, 148AB, 149AB, 169AB, 179AB.

6Math 20F and MAE 140 may be taken concurrently.

7Technical elective (TE) courses must be selected from a departmental approved list. Consult the Student Affairs Office.

(ABET-Accredited Program)

1Chem 7L may be taken concurrently with Chem 6C or in any quarter within the first two years after completion of Chem 6B.

2BENG 1 may be taken in sophomore year.

3Continuing students who have completed MAE 9 or 10 are NOT REQUIRED to take MAE 8 and future Transfer students who have completed a course equivalent to MAE 9 or 10 are exempted from completing MAE 8 until fall 2013.

4Ten HSS courses are listed here; individual college requirements may be higher.

5Recommended course, not required.

6Design elective (DE) courses must be selected from a two-quarter sequence, BENG 119AB, 126AB, 127AB, 128AB, 129AB, 139AB, 147AB, 148AB, 149AB, 169AB, 179AB.

7Technical elective (TE) courses must be selected from a departmental approved list. Consult the Student Affairs Office.

(ABET Accreditation to be sought.)

1Ten HSS courses are listed here; individual college requirements may be higher.

2Technical elective (TE) courses must be selected from a departmental approved list. Consult the Student Affairs Office.

3Design elective (DE) courses must be selected from a two-quarter sequence, BENG 119AB, 126AB, 127AB, 128AB, 129AB, 139AB, 147AB, 148AB, 149AB, 169AB, 179AB.

4Recommended course, not required.

(Not accredited by a Commission of ABET.)

1Students may take the slower paced version, CSE 8A-B, instead of CSE 11.

2Technical elective (TE) courses must be selected from a departmental approved list. Consult the Student Affairs Office.

3Ten HSS courses are listed here; individual college requirements may be higher.

4Design elective (DE) courses must be selected from a two-quarter sequence: BENG 119A-B, 126A-B, 127A-B, 128A-B, 129A-B, 139A-B, 147A-B, 148A-B, 149A-B, 169A-B, 179A-B.

Because of heavy student interest in the majors in the Department of Bioengineering and the limited resources available to accommodate this demand, maintenance of a high quality program makes it necessary to limit enrollments to the most qualified students.

Students admitted into a capped major who transfer out of the capped major may transfer back into it one time without meeting the full requirements for continuing student admission prior to the end of their sophomore year, provided they are in good academic standing.

Freshman students who have excelled in high school and have declared Bioengineering, Bioengineering: Biotechnology, Bioengineering: Bioinformatics, or Bioengineering: BioSystems on their UC San Diego application are eligible for direct admission into those majors.

The UC San Diego Office of Admissions and Relations with Schools will calculate an admissions target number and admit the appropriate number of incoming freshmen into each impacted major using the UC San Diego Holistic Review score as a ranking method. Students who meet the UC San Diego admission criteria will be admitted into their chosen capped major, starting with the student having the highest holistic review score, until the admission target number is reached. These students will be notified directly by the Office of Admissions and Relations with Schools whether they have been admitted into their chosen capped major.

Freshman students who applied but were not admitted directly from high school into the capped Bioengineering, Bioengineering: Biotechnology, Bioengineering: Bioinformatics, or Bioengineering: BioSystems majors will be admitted into the major indicated as their second choice on the UC application (providing it is an open major).

Each fall quarter, a certain number (determined on an annual basis) of continuing sophomore students who apply will be selected to enter the capped Bioengineering, Bioengineering: Biotechnology, Bioengineering: Bioinformatics, or Bioengineering: BioSystems majors. Interested continuing students must not be past sophomore standing, as time to graduation would be delayed since departmental upper-division courses are currently offered only once a year.

Continuing students will be required to complete the following courses prior to applying, depending on their major of choice:

Bioengineering and Bioengineering: Biotechnology: BILD 1; Chem 6A-B; MAE 8; Math 20A-C; Physics 2A-B.

Bioengineering: Bioinformatics: BILD 1; Chem 6A-B; CSE 11 (or 8A-B); Math 20A-C; Phys 2A-B.

Bioengineering: BioSystems: ECE 35; Chem 6A-B; Math 20A-C, Phys 2A-B.

Students will receive e-mail instructions from the Bioengineering Student Affairs Office concerning completion of an online application at the beginning of fall quarter of their second year. Online applications must be submitted by Friday of the first week of instruction in fall quarter. Continuing students applications will be ranked according to the GPA obtained in the required courses only.

Applications to a capped major will be approved, starting with the student having the highest GPA in the required courses, until the predetermined target number is reached. The Bioengineering Student Affairs Office will notify students in a timely manner who are successful in transitioning into one of the capped majors to officially declare the appropriate major online via the Major/Minor link under Toolbox at http://tritonlink.ucsd.edu.

Continuing students who apply and are unable to transition into one of the capped majors will also be notified of their status in a timely manner by the Bioengineering Student Affairs Office.

General advice: Transfer students are advised to complete the following courses for their major before enrolling at UC San Diego. Preparing well for the major helps students move efficiently toward graduation.

The UC San Diego Office of Admissions and Relations with Schools will calculate an admissions target number and admit the appropriate number of incoming transfer students into each capped major, based on the community college GPA. Additionally, transfer students should have completed the following courses for admission equivalent to UC San Diego:

Bioengineering: Math 20A-B-C-D; Physics 2A-B and 2BL-CL; and Chemistry 6A-B

Bioengineering: Biotechnology: Math 20A-B-C-D; Physics 2A-B and 2CL; and Chemistry 6A-B

Bioengineering: Bioinformatics and Bioengineering: BioSystems: Math 20A-B-C-D; Physics 2A-B; and Chemistry 6A-B

Students who meet the UC San Diego admission criteria will be admitted into their chosen capped major, starting with the student having the highest community college GPA, until the admission target number is reached. (At least a 3.2 GPA in the community college transfer courses, and a 3.4 GPA in math, physics, and computer science courses, are likely to be needed to gain admission.) These students will be notified directly by the Office of Admissions and Relations with Schools whether they have been admitted into their chosen impacted major.

Transfer students who applied but were not admitted directly from community college into the capped Bioengineering, Bioengineering: Biotechnology, Bioengineering: Bioinformatics, or Bioengineering: BioSystems majors will be admitted into the major indicated as their second choice on the UC application (providing it is an open major).

Upon admission to a major, students are encouraged to seek advice from departmental staff in the Bioengineering Student Affairs Office, Room 141, Powell-Focht Bioengineering Hall, to plan a program of study. Students are expected to chart their progress within their major. As the department may make a small number of course and/or curricular changes every year, it is imperative that students check their e-mail for updates and consult a bioengineering undergraduate adviser on an annual basis.

To enroll in any courses required for a bioengineering major, a student must have completed prerequisite courses. (The department does not consider D or F grades as adequate preparation for subsequent material.) Where these prerequisite course work and other restrictions apply, the registrar will not enroll other students except by department approval. Students are advised that they may be dropped from course rosters if prerequisites have not been met.

Bioengineering courses are typically offered only once a year and therefore should be taken in the recommended sequence. If courses are taken out of sequence, it may not always be possible to enroll in courses as desired or needed for timely graduation. If this occurs, students should seek immediate departmental advice.

Programmatic advice may be obtained from the Student Affairs Office. In addition, technical advice may be obtained from a specific bioengineering faculty adviser assigned to each student upon admission to the major.

Exceptions to any program or course requirements are possible if approved by the Undergraduate Studies Committee before the courses in question are taken. Petitions may be obtained from the Bioengineering Student Affairs Office.

A capstone design course sequence is required for senior level students in the Bioengineering, Bioengineering: Biotechnology, and Bioengineering: BioSystems majors. The capstone design course sequence consists of a multiquarter upper-division sequence of courses that totals ten quarter-units and includes (1) a series of four one-unit courses on selection (BENG 187A), design (BENG 187B), implementation (BENG 187C), and presentation (BENG 187D) of design projects, with consideration of professional issues, and (2) a sequence of two three-unit laboratory design projects, offered in many of the primary areas of bioengineering, including biomechanics (BENG 119AB), systems bioengineering (BENG 127AB, 128AB, 129AB), nanoscale and molecular bioengineering (BENG 139AB), organ system bioengineering (BENG 147AB, 148AB, 149AB), tissue engineering and regenerative medicine (BENG 169AB), and bioinstrumentation (BENG 179AB). The design projects and presentations will be performed by student teams in the course sequence.

Under the guidance of a bioengineering faculty member, lower- and upper-division level bioengineering students have opportunities to participate in independent study and research.

Upper-division bioengineering students may take BENG 199, Independent Study for Undergraduates. Lower-division bioengineering students may enroll in BENG 99, which is similar to BENG 199 except that less background in the curriculum is needed. These courses are taken as electives on a P/NP basis. Under certain conditions, a BENG 199 course may be used to satisfy upper-division technical elective course requirements for the major. Students interested in this alternative must identify a faculty member with whom they wish to work and propose a two-quarter research or study topic for Bioengineering, Bioengineering: Biotechnology, and Bioengineering: BioSystems majors. Completion of two consecutive quarters of BENG 199 will satisfy both technical elective requirements in the Bioengineering, Bioengineering: Biotechnology, and Bioengineering: BioSystems majors. Bioengineering: Bioinformatics majors may satisfy up to two of the three technical elective requirements in those majors by completion of BENG 199 courses. After obtaining the faculty advisers concurrence on the topic and scope of the study, the student must submit a Special Studies form (each quarter) and a BENG 199 as Technical Elective Contract to the Undergraduate Studies Committee. These forms must be completed, approved, and processed prior to the beginning of the quarter in which the course is to be taken.

Students interested in participating in the instructional activities of the department may take BENG 195, Undergraduate Teaching as an elective on a P/NP basis. Policy in this regard may be obtained from the Student Affairs Office.

The Department of Bioengineering offers two industry-related programs: the Industrial Internship Program for undergraduates and the Graduate Industrial Training Program for graduate students. Both industrial programs are designed to complement the departments academic curriculum with practical industry experience. Students interested in these programs should contact the Bioengineering Student Affairs Office well in advance of the quarter in which they would like to start their internship.

The Industrial Internship Program is available to undergraduate students who have completed all lower-division course requirements. Academic credit under BENG 196, Bioengineering Industrial Internship, can be earned by spending ten weeks or more as interns in an industrial setting. The intern may be involved in a range of activities, including design, analysis, manufacturing, testing, regulatory affairs, etc., under the direction of a mentor in the workplace. At the completion of the internship experience, students are required to submit a brief report to the mentor and faculty adviser describing their activities. Up to four units of BENG 196 may be used towards technical elective credit.

The Graduate Industrial Training Program is designed for students in the Master of Engineering Degree Program. This program serves to significantly enhance the professional development of MEng students in preparation for leadership in the bioengineering industry. Students will complete an independent industrial bioengineering project in a company setting under the direction of an industrial and faculty adviser.

Original post:
Bioengineering - University of California, San Diego

Director of Bioengineering Institute receives international accolade … – Voxy

The Director of the University of Aucklands Bioengineering Institute (ABI) has been awarded an honorary doctorate from the University of Sheffield, in the United Kingdom.

Distinguished Professor Peter Hunter, who is renowned for his work in the fields of in silico medicine and computational physiology, will receive the doctorate in engineering on 18 July 2017.

"This award means a lot to me," says Professor Hunter. "The Insigneo Institute led by Professor Marco Viceconti at the University of Sheffield is the preeminent bioengineering institute in Europe."

Professor Hunter completed his engineering degrees at the University of Auckland before undertaking his DPhil (PhD) in Physiology at the University of Oxford. Since then he has pioneered the use of computational methods for understanding the integrated physiological function of the body in terms of the structure and function of tissues, cells and proteins.

Alongside his role as Director of ABI and Professor of Engineering Science at the University of Auckland, Professor Hunter is also Director of Computational Physiology at Oxford University, and Director of the Medical Technologies Centre of Research Excellence (MedTech CoRE) hosted by the University of Auckland. He was appointed to the NZ Order of Merit in 2010 and in 2009 received an honorary doctorate from the University of Nottingham.

Read more here:
Director of Bioengineering Institute receives international accolade ... - Voxy

The Moral Question That Stanford Asks Its Bioengineering Students – The Atlantic

When students in Stanford Universitys Introduction to Bioengineering course sit for their final exams, the first question that they have to answer is about our ability to write DNA.

Scientists have fully sequenced the genomes of humans, trees, octopuses, bacteria, and thousands of other species. But it may soon become possible to not just read large genomes but also to write themsynthesizing them from scratch. Imagine a music synthesizer with only four keys, said Stanford professor Drew Endy to the audience at the Aspen Ideas Festival, which is co-hosted by the Aspen Institute and The Atlantic. Each represents one of the four building blocks of DNAA, C, G, and T. Press the keys in sequence and you can print out whatever stretch of DNA you like.

In 2010, one group did this for a bacterium with an exceptionally tiny genome, crafting all million or so letters of its DNA and implanting it into a hollow cell. Another team is part-way through writing the more complex genome of bakers yeast, with 12 million letters. The human genome is 300 times bigger, and as I reported last month, others are trying to build the technology that will allow them to create genomes of this size.

For now, thats prohibitively expensive, but it wont always be that way. In 2003, it cost 4 dollars to press one of the keys on Endys hypothetical synthesizer. This month, it costs just two centsa 200-fold decrease in price in just 14 years. In the same time frame, the cost of tuition at Stanford has doubled, and is now around $50,000. Given all of that, the first question that Stanfords budding bioengineers get is this:

At what point will the cost of printing DNA to create a human equal the cost of teaching a student in Stanford?

And the answer is: 19 years from today.

There are a lot of assumptions built into that answer. It will take a lot of technological advances to print the complex genomes of humans and to keep the costs falling at the same pace as they have done. But bearing those assumptions in mind, the problem is a mathematical one, and the students are graded on their ability to solve it. But the follow-up question is a little more complicated:

If you and your future partner are planning to have kids, would you start saving money for college tuition, or for printing the genome of your offspring?

The question tends to split students down the line, says Endy. About 60 percent say that printing a genome is wrong, and flies against what it means to be a parent. They prize the special nature of education and would opt to save for the tuition. But around 40 percent of the class will say that the value of education may change in the future, and if genetic technology becomes mature, and allows them to secure advantages for them and their lineage, they might as well do that.

There is clearly no right answer to the second question, and students are graded on their reasoning rather than their conclusion. But when both questions are considered together, they suggest, Endy says, that in the order of a human generation, well have to face possibilities that are much stranger than what were prepared for.

Read the original post:
The Moral Question That Stanford Asks Its Bioengineering Students - The Atlantic

Visiongain Report Looks at Opportunities Within the $23bn Cell Therapy Technologies Market – PR Newswire UK

Cell Therapy Technologies Market Forecast 2020-2030

LONDON, March 25, 2020 /PRNewswire/ -- Consumables, Equipment, System & Software, Cell Processing, Cell Processing Equipment, Single Use Equipment, Cell Preservation, Distribution, Handling, Process Monitoring & Quality Control, Human Cells, Animal Cells, Life Sciences & Research Companies, Research Institutes

Visiongain estimates that the global cell therapy technologies market will grow at a CAGR of 15% in the first half of the forecast period. In 2020, North America is estimated to hold 38% of the global cell therapy technologies market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new201-page reportyou will receive104 tables and 110 figures all unavailable elsewhere.

The 201-page Visiongain report provides clear detailed insight into the cell therapy technologies market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

To request sample pages from this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/cell-therapy-technologies-market-forecast-2020-2030/#download_sampe_div

Report Scope

Global Cell Therapy Technologies Marketfrom2020-2030

Forecast of the Global Cell Therapy Technologies Market byType of Product: Consumables Equipment:Cell Processing Equipment, Single Use Equipment, Other Equipment System & Software

Forecast of the Global Cell Therapy Technologies byProcess Type: Cell processing Cell preservation, distribution and handling Process monitoring and quality control

Forecast of the Global Cell Therapy Technologies byCell Type: Human cells:Stem cells, Differentiated cells Animal cells

Forecast of the Global Cell Therapy Technologies byEnd User: Life Sciences and Research Companies Research Institutes

This report provides individual revenue forecasts to 2030 for thesenational markets: The US Canada Mexico UK Germany France Italy Spain Japan China India South Korea Singapore Malaysia Russia Brazil Argentina UAE South Africa Nigeria Mexico

Our study discusses the selectedleading companiesthat are the major players in the respiratory inhalers market: GE Healthcare Lonza Group Merck KGaA Terumo Bct, Inc. Thermo Fisher Scientific, Inc. & Other Companies

For the leading companies, we feature product portfolios, business segment breakdowns, recent developments & key expansion strategies etc.

This report discussesfactors that drive and restrainthis market. As well asopportunitiesandchallengesfaced by this market.

This report discusses thePorter's Five Forces Analysisof the Cell Therapy Technologies Market.

Key questions answered by this report: How is the Cell Therapy Technologies Market evolving? What is driving and restraining factors of the Cell Therapy Technologies Market? What are the market shares of each segment of the overall Cell Therapy Technologies Market in 2020? How will each Cell Therapy Technologies submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2030? How will the market shares for each Cell Therapy Technologies submarket develop from 2021 to 2030? What will be the main driver for the overall market from 2021 to 2030? Will leading national Cell Therapy Technologies Markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others? How will the market shares of the national markets change by 2030 and which geographical region will lead the market in 2030? Who are the leading players and what are their prospects over the forecast period? How will the industry evolve during the period between 2020 and 2030?

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/cell-therapy-technologies-market-forecast-2020-2030/

Did you know that we also offer a report add-on service? Email sara.peerun@visiongain.comto discuss any customized research needs you may have.

Companies covered in the report include:

Affymetrix, Inc.AkouosAllCellsApplikon Biotechnology Inc.ATLATL CentreAutolus LimitedBeckman Coulter, Inc.Becton, Dickinson and CompanyBioengineering AGBiological IndustriesBioWa, IncBrammer BioC.R. Bard, Inc.CaridianBCT, IncCell and Gene Therapy Asia Technology CentreCentre for Process Innovation (CPI)CMC Biologics (Asahi Glass Co.)Cobra BiologicsCocoon PlatformCryoportDanaher CorporationDiNAQOR AGEMD Performance MaterialsEMD SeronoEppendorf AGEuropean Molecular Biology Laboratory (EMBL)Finesse Solutions, Inc.Flexsafe RM TXFloDesign SonicsFlowJo, LLCFood and Drug Administration (FDA)Gamida CellG-CON ManufacturingGE healthcareGenScriptInfors HTIntegrated DNA Technologies, Inc.LaVision BioTecLonza Group, GE HealthcareMassachusetts Eye and Ear (MEE)Meissner Filtration Products, Inc.Merck KGaAMerck SeronoMesoblastMilliporeSigmaMiltenyi BiotecNova BiomedicalPall Corporation (Pall)Patheon N.V.Penn State UniversityPharmaCell B.VSartorius AGSartorius Stedim BiotechScinogySelecta Biosciences, IncSiemensSolaris BiotechStafa Cellular TherapyStafaCTStemcell TechnologiesTerumo Bct, Inc. (A Subsidiary of Terumo Corporation)Thermo Fisher Scientific, Inc.Tillotts Pharma AGTranstem LabUniCAR TherapyWorld Courier

To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com

Related reports:

Global Stem Cell Technologies and Applications Market 2019-2029

Biobanking Market Forecasts 2019-2029

Biologics Market Trends and Forecasts 2019-2029

Global Bioreactors Market 2020-2030

Global Precision Medicine Market Forecast 2019-2029

Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg

SOURCE Visiongain

See original here:
Visiongain Report Looks at Opportunities Within the $23bn Cell Therapy Technologies Market - PR Newswire UK

Cysteine Industry Forecast and Growth Opportunities 2020-2025 | COVID-19 Impact | Wacker Chemie AG, Ajinomoto Pte.Ltd, Donboo Amino Acid Co. Ltd, Wuxi…

A new intelligence report Cysteine Market has been recently added to Adroit Market Research collection of top-line market research reports. Global Cysteine Market report is a meticulous all-inclusive analysis of the market that offers access to direct first-hand insights on the growth trail of market in near term and long term. On the basis of factual information sourced from authentic industry experts and extensive primary industry research, the report offers insights on the historic growth pattern of Cysteine Market and current market scenario. It then provides short- and long-term market growth projections.

Request Free Sample Report of Cysteine Market at: https://www.adroitmarketresearch.com/contacts/request-sample/304

Projections are purely based on the detailed analysis of key market dynamics that are expected to influence Cysteine Market performance and their intensity of impacting market growth over the course of assessment period.

In addition to evaluation of dynamics, the report provides in-depth examination of key industry trends that are expected to act more prominently in global Cysteine Market. The study also offers valued information about the existing and upcoming growth opportunities in Cysteine Market that the key players and new market entrants can capitalize on.

Competitive companies and manufacturers in global market

Wacker Chemie AG, Ajinomoto Pte.Ltd, Donboo Amino Acid Co. Ltd, Wuxi Bikang Bioengineering Co., Nippon Rika Co.Ltd, Merck and Co., Inc.

View Full Report at: https://www.adroitmarketresearch.com/industry-reports/cysteine-market

Opportunity assessment offered in this Cysteine Market report is important in terms of understanding the lucrative areas of investment, which prove to be the actionable insights for leading market players, suppliers, distributors, and other stakeholders in Cysteine Market.

In-depth global Cysteine Market taxonomy presented in this report provides detailed insights about each of the market segments and their sub-segments, which are categorized based on t par various parameters. An exhaustive regional analysis of global Cysteine Market breaks down global market landscape into key geographies.

Regional outlook and country-wise analysis of Cysteine Market allows for the evaluation of multi-faceted performance of market in all the key economies. This information intends to offer a broader scope of report to readers and identify the most relevant profitable areas in global market place.

Global Cysteine market is segmented based by type, application and region.

Based on Type, the market has been segmented into:

Based on source, l- cysteine is segmented into (Natural through feathers and human hair, Synthetic through microbial fermentation), Based on the grade, l- cysteine is segmented into (Food grade, Tech grade, Pharma grade), Based on the Industrial use, l- cysteine is segmented into(Food, Pharmaceuticals, Cosmetics)

Based on application, the market has been segmented into:

Based on Applications, l- cysteine is segmented into (Conditioner, Flavor enhancer, Reducing agent, Radical scavenger)

Key Regions and Countries Covered in Global Cysteine Market Report-1. North America (US)2. Europe (Germany, France, UK)3. Asia-Pacific (China, Japan, India)4. Latin America (Brazil)5. The Middle East & Africa

Taxonomy and geographical analysis of the global Cysteine Market enables readers to spot profits in existing opportunities and capture upcoming growth opportunities even before they approach the market place. The analysis offered in report is purely intended to unroll the economic, social, regulatory and political scenarios of the market specific to each region and country, which could help potential market entrants in Cysteine Market landscape to understand the nitty-gritty of target market areas and devise their strategies accordingly.

Cysteine Market Table of Contents1. Research Methodology2. Cysteine Market Overview3. Global Cysteine Market by Type4. Global Cysteine Market by application5. Global Cysteine Market by region6. Global Cysteine Market Production and Consumption Analysis By Region7. Market Determinants8. Global Cysteine Market Competition by Manufacturers9. Global Cysteine Market Manufacturers Analysis10. Cysteine Market Value Chain Analysis

Do you have any query or specific requirement? Ask to our industry expert at: https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/304

About Us :

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX75204, U.S.A.Phone No.: USA: +1 972-362 -8199/ +91 9665341414

Go here to read the rest:
Cysteine Industry Forecast and Growth Opportunities 2020-2025 | COVID-19 Impact | Wacker Chemie AG, Ajinomoto Pte.Ltd, Donboo Amino Acid Co. Ltd, Wuxi...

People and Professions: Reported March 15, 2020 – Herald-Whig

Posted: Mar. 15, 2020 1:00 am

Accreditations/Certifications

Eric Basinger of Klingner and Associates P.C. has earned his professional land surveyor license from the Illinois Department of Financial and Professional Regulation. Basinger, who works in Klingner's Quincy office, has been a survey technician with the firm since 2007. He has a bachelor of science degree in bioengineering and another in psychology, both from the University of Illinois Urbana-Champaign.

Dawn Crabtree, a nurse with the Blessing Diabetes Center, has earned certified diabetes care and educational specialist status from the National Certification Board for Diabetes Educators. She has been on the Blessing Hospital nursing staff for 15 years. Crabtree has a bachelor of science in nursing degree from Chamberlain College and an associate degree in nursing from John Wood Community College.

Appointments

Kenneth Reasoner has been named the Hannibal Board of Public Works general manager. He plans to start the job in mid-April. He's now director of management services at City Utilities in Springfield. Reasoner is a certified public accountant and started his career with the Missouri State Auditor's Office in Jefferson City.

Brandi Venvertloh, an associate professor at Blessing-Rieman College of Nursing and Health Sciences, has been appointed pre-licensure bachelor of science in nursing coordinator. She has a bachelor of science degree in nursing and a master of science degree in nursing from the college and a PhD in nursing education from the University of Northern Colorado.

Honors

Gerard Fischer, an American Family Insurance agency owner in Quincy, has been recognized for providing outstanding customer experience under the American Star Excellence in Customer Experience Certification Program. Fischer has been an agency owner since 1995. He also has offices in Godfrey, and Edwardsville, Ill.

Read more from the original source:
People and Professions: Reported March 15, 2020 - Herald-Whig

Researchers Find "Groovy" Way to Grow Human Tissue – Plastics Today

Researchers have developed a new bioprinting method that allows researchers to grow different types of living cells at the same time into implants using the same foundational technologies.

The method, developed by a team at Rice University, is an advancement in how living cells are printed that could be used to develop implants that can help heal injuries, among other things, said Antonio Mikos, a professor of bioengineering and chemical and biomolecular engineering at the university.

Mikos led the team that developed the technique, which uses grooves to seed sophisticated, 3D-printed tissue-engineering scaffolds. Previously, these scaffoldswhich are used to grow human tissuecould only have a uniform distribution of cells, he explained.

If we wanted different cell populations at different points in the scaffold, we could not do that, Mikos said in a press statement.

Now researchers can do that through a new process that carves grooves into plastic threads used to build the scaffolds, he said. Scientists then seed the grooves with cells or other bioactive agents to help growth new tissue.

Creating Living Tissue

In the technique, a 3D printer cuts the grooves into a thermoplastic, inserting the cells at the proper temperature and creating a three-dimensional implant--based on medical images--in a single process, researchers said.

The fibers are cylinders that we engrave with a needle to give it a groove as its printing, Rice research scientist Maryam Elizondo said in a press statement. Once the groove is set and cooled just enough, the printer then deposits a cell-infused ink for every fiber for every layer of the scaffold, she said.

It takes about half an hour to completely print a thumbnail-sized implant using the process with the grooved threads, which are about 800 microns wide, Elizondo added.

Biodegradable Implants for Healing

Researchers published a paper on their work in the journal Bioprinting.

The result of the bioprinting method is hard implants that can be surgically inserted to heal bone, cartilage or muscle, Mikos said. Like hydrogels that are currently used as implants inside the body, the biocompatible implants would degrade over time and leave only natural tissue, he said.

The new scaffold-fabrication process has advantages over previous ones because it can protect cells from the heat and shear stresses that can kill them, researchers said. It also provides a way to layer cells in one mechanically stable foundation that ultimately become different kinds of tissue, like bone and cartilage, they said.

The major innovation here is our ability to spatially load a scaffold that is 3D-printed with different cell populations and with different bioactive molecules, Mikos said.

Elizabeth Montalbano is a freelance writer who has written about technology and culture for more than 20 years. She has lived and worked as a professional journalist in Phoenix, San Francisco and New York City. In her free time she enjoys surfing, traveling, music, yoga and cooking. She currently resides in a village on the southwest coast of Portugal.

See the rest here:
Researchers Find "Groovy" Way to Grow Human Tissue - Plastics Today

Smart microneedle insulin patch could make it easier to treat diabetes – Digital Trends

Close to 10% of the U.S. population, around 30.3 million people, have diabetes. A new treatment delivery system created by bioengineers at the University of North Carolina and theUniversity of California, Los Angeles could help make life easier for them via a smart insulin patch thats about the size of a quarter. All a patient would need to use it would be to slap on a new patch at the start of the day, after which it would monitor and manage glucose levels for the next 24 hours.

It is smart and simple, which means it could help enhance the health and quality of life for people with diabetes, Zhen Gu, the study leader and a professor of bioengineering at the UCLA Samueli School of Engineering, told Digital Trends. It is a smart glucose-responsive insulin release device because it can respond to high blood sugar levels and release only the necessary insulin dosage, thus reducing the risk of hypoglycemia. This is a small and disposable device, so it is very simple and convenient to use; one can remove the patch any time to stop the administration of insulin.

The glucose-monitoring adhesive patch is covered in tiny microneedles, each one less than a millimeter in length. They are made from a glucose-sensing polymer and come pre-loaded with insulin. When the patch is applied, the microneedles penetrate the skin and start measuring blood sugar levels. If the glucose levels increase, the polymer triggers the release of insulin. At the point at which levels return to normal, the patchs insulin delivery also slows down. While this approach still involves pricking the patient with a needle, these needles are much smaller than regular needles. As a result, the patch is less painful than an ordinary injection.

So far, the patch has been successful in studies involving pigs. The researchers were able to use it to successfully control the glucose levels in these animals, which had Type I diabetes, for around 20 hours. Next, the researchers are hoping to progress to further trials, with the goal of commercializing their technology.

This patch has already been accepted by FDAs emerging technology programs for clinical trial applications, Gu said.

A paper describing the research was recently published in the journal Nature Biomedical Engineering.

See the original post:
Smart microneedle insulin patch could make it easier to treat diabetes - Digital Trends

Helping Your Ag Customers Improve Their Farm Business IQ – ABA Banking Journal

By Carrie Clark Carlsen

While we have a keynote speaker, we also bring in a commodities outlook guy, an update on crop insurance, some artificial intelligence, and someone from a machinery equipment dealer in New York, explains Shan Hanes, the banks president and CEO.

Weve had an expert panel on everything you wanted to ask your banker but couldnt, he adds with a chuckle. We had bankers up here on stage and it was free reinattack your banker!

Events like Farmer Focus Day are just one way that Americas ag bankers are tackling a perennial farm challenge: improving ag producers business acumen, especially in an era of disruption. Changes in agriculture are going to accelerate over the next 10 years, says David Kohl, an emeritus ag economist at Virginia Techespecially in areas like technology, bioengineering and big data. Agribusinesses are increasing in complexity, and operations are growing in size at a time when many farms are transitioning to the next generation.

We are transitioning from the baby boom generation to Generation X, millennials, pick your generation, and as that changes, technology is changing, the cost of farming is changing, farm sizes are getting biggerand you cant farm the way you used to farm, adds Tony Hotchkiss, EVP for ag banking at Regions Bank. Farmers have done a lot to upgrade the tech they usebut many are still running the farm the way they used to.

I often hear weve never done it that way or Ive never had to do it that way, Hotchkiss explains, speaking at the recent American Bankers Association Agricultural Bankers Conference. Its very important that as bankers we take ownership of this issue and make sure we are introducing concepts and topics, and helping producers understand the new complexity of farming.

In navigating these sweeping changes, Kohl emphasizes that farm business IQ is the common denominator for producer success. And thats an opportunity for ag bankers to team up with customers as their trusted advisersdelivering candid conversations, constructive coaching and community-building events. After all, when ag borrowers develop their business IQ, it pays off for the lender as well.

It all starts with dialogue. Scott Hauseman, a senior ag lender at Fulton Bank in Pennsylvania encourages his team to consider expectations with their producers; ask about accruals; talk about sales, credit quality and exposure; and do stress testing with lots of of what-if questions: If we go to covenants at this level, whats that feel like? Are you comfortable?

You need to be able to talk to your borrower about cost of production, where maybe in past eras we didnt really carebecause in our part of the world we had lots of equity and usually cash flow drove decisioning, he adds. Thats a big change because of things were seeing and the times we are in.

Meanwhile, Hotchkiss instructs his lenders to challenge their customers thinking, have them look at their margins, study statistics based on acreage and calculate the cost of production. If a producer prefers the dirt side of farming, his lender should be asking what hes doing to make sure that the business side is managed properly.

Hard conversations are where things begin, but producers need to move beyond questions and start finding their own answers. Hauseman emphasizes the importance of sharing dataand analytical tools to employ itwith farm customers. His personal philosophy is that if hes making credit decisions on customer financials, he should be willing to give them the spread that he made that decision on.

Shan Hanes agrees. The bank felt that the number-one thing that ag producers were missing was knowing their breakeven costs, he said. Fifteen years ago, Hanes bank developed a breakeven analysis spreadsheet for customers to use. The reason I think thats important is as events happen people can make adjustments to that spreadsheet.

At the beginning of the year, Hanes also has his ag customers write down their projected cash flows, including living expenses, and set objectives for the year. He asks them what they expect the market high and low to be. It forces them to engage in the marketing process, he says.

Hauseman uses coaching models with his loan officers, which he hopes they will use with customers. He asks his lenders: Do you have the right financial statements that are even testable? Or accrual statements?Ive seen that this coaching model goes over very well, Hauseman continues. Ive seen some really good discussions with customers because lenders have been taught some skill and capability levels that they wouldnt have had without that model in place.

Hotchkiss encourages his ag lenders at Regions Bank to use this coaching approach to prove their value as a partner who can do more than lend money. He tells lenders: Share data with your producers, and show them, Based on what was reported, heres what your peers are doing and heres where you are.

Additionally, Regions Bank is employing technology to deliver coaching on succession planning, land trusts, diversification and many other topics. Younger row-crop farmers prefer high-tech interfaces, Hotchkiss says. We are generating more interest with webcasts and podcasts, where we send them links. Theyre watching these little 10-15 minute snippets on very specific topics while they are in their combines.

Events like Farmer Focus Day build on the tough conversations and one-on-one coaching to provide a fun yet educational group dynamic. Another example Hanes uses: the marketing game. Over the course of several weeks, six to eight novice and experienced farmers are intermingled at tables for role-playing and problem solving. Each group is assigned an actual farm operation case study involving a commodity, specific market conditions, financing options and other variables.

In each weekly meeting, new variables are presented, such as developments in world trade, price fluctuations and/or unplanned expenses. During the simulation, Hanes says young and old engage with his lenders and with each otherrooting for and learning from each other, working together to come up with a viable plan for a profitable farm operation.

Hanes was surprised by a corollary outcomeone that has nothing to do with business IQ, but one that lays the groundwork for producer success. We have seen those older farmers who were looking for their next tenant sit at a table and build a relationship, he reflects. They made a friendship, they stayed connected to each other and we were able to provide an environment where they could transition from one generation to the next.

Building farm business IQit brings bankers and farmers closer together.

See the original post:
Helping Your Ag Customers Improve Their Farm Business IQ - ABA Banking Journal

Award-Winning Trinity Scientists to Share Over 6m in Research Funding – The University Times

Srn FogartyAssistant News Editor

Four Trinity researchers have been awarded a combined total of over 6 million from a Science Foundation Ireland (SFI) scheme that recruits and retains emerging early career researchers.

Ten recipients were honoured today by President Michael D Higgins as part of the President of Ireland Future Research Leaders Programme including three from University College Dublin (UCD), two from Maynooth University and one from the Dublin Institute for Advanced Studies (DIAS).

The researchers fields include lung disease, ageing, traumatic brain injury, bowel and gastrointestinal diseases and sensors. The four Trinity researchers are Dr Suzanne Cloonan, Dr David Loane, Prof Neasa OConnor and Prof Roman Romero-Ortuno.

In a press statement, Prof Linda Doyle, Trinitys Dean of Research, said: The SFI President of Ireland Future Research Leader Awards are crucial in attracting talent to Ireland. We are incredibly proud of the four academics who have come to Trinity through this scheme.

The four awardees, Doyle said, have already demonstrated strong leadership in their fields. The research they do will have real impact on peoples lives and I am excited to see what they will accomplish as a result of the support of this scheme.

Programmes like this, she added, are an essential part of creating a balanced research ecosystem, and the broad range of projects that have been supported this year shows the need to ensure that more funding continues to be made available to individual researchers. I extend my sincere congratulations to all this years Future Research Leaders.

In a press statement, Cloonan, whose research is focused on lung and respiratory diseases, said: I am delighted and honoured to receive this prestigious award. It has allowed me to develop a cutting-edge interdisciplinary research programme at Trinity College Dublin, to understand and develop new treatment approaches for Chronic Obstructive Pulmonary Disease (COPD), a debilitating chronic lung disease that remains the fourth leading cause of death in Ireland.

This work, Cloonan said, will not only place Ireland on the map for world-class COPD research but will also raise much needed awareness for COPD and COPD-related research.

OConnor, an assistant professor of zoology in Trinity, said that I am truly honoured to receive this award and immensely excited to continue our work with a growing team at Trinity College. We will use ecological knowledge to unlock the potential of Irelands marine resources.

She continued: By cultivating seaweed to harness products for bioengineering and biofuels, we will be helping to develop new tools for the treatment of debilitating diseases, such as osteoarthritis, while also combating climate change by enhancing carbon sequestration and also enriching local coastal habitats.

Romero-Ortuno is an associate professor in Medical Gerontology, and works closely with The Irish Longitudinal Study on Ageing (TILDA), which is Trinity-based. He said: I am delighted to have received this SFI President of Ireland Future Research Leaders award.

As a clinician scientist, this award will enable me to build the human and computational capability to investigate a highly complex issue that is of immense importance to our ageing society, he added.

Read the original:
Award-Winning Trinity Scientists to Share Over 6m in Research Funding - The University Times

A science discovery made in the shade – Yale News

Blue-green algae are getting their day in the sun not that they need much of it. A new analysis of their molecular makeup could lead to better solar technology and crops that grow just fine with less sunlight.

In a new study in the journal Science Advances, researchers from Yale, Arizona State University, and Penn State University report on structural properties that allow certain blue-green algae to thrive under lower-sunlight conditions. Its the first time that scientists have been able to see these structural properties, offering clues for bioengineering hardier crops and designing more effective solar cells.

Blue-green algae, also called cyanobacteria, are microscopic organisms that grow in both water and terrestrial environments. They contribute as much as half of the photosynthesis taking place on Earth, thanks to their ability to thrive in a wide range of environments. Photosynthesis is the process by which plants and algae generate the atmospheric oxygen that sustains life on the planet.

Certain organisms can live off of light, while also being in the shade. Understanding how that works is remarkable, said Christopher Gisriel, a postdoctoral associate in chemistry at Yale and first author of the study.

Donald Bryant of Pennsylvania State University is the studys senior author.

To find out why cyanobacteria are so successful, the researchers studied Fischerella thermalis, a terrestrial cyanobacteria.

When Fischerella thermalis is deprived of bright, high-energy sunlight (called white light), it switches gears. It instead starts absorbing low-energy sunlight, known as far-red light.

How does it make this switch? Gisriel said its all about the chlorophyll the green pigment responsible for harvesting light within plants. The typical form of chlorophyll, called chlorophyll a, absorbs white light; an alternate form, called chlorophyll f, is able to absorb far-red light.

These organisms that can absorb far-red light, can actually switch back and forth, Gisriel said. If you put them in white light, they only use chlorophyll a, and theyre just like all the other cyanobacteria. But if you move them to the shade, where they have more of this lower-energy, far-red light, they actually switch out some of the chlorophyll as for chlorophyll f, and that allows them to absorb far-red light. Thats a testament to the plasticity of photosynthesis it can adapt to many environments, which I think is a pretty incredible mechanism.

Gisriel said as much as 25% of all cyanobacteria may use far-red light for photosynthesis. It allows them to grow under a forest canopy and beneath other plants on the surface of a pond, he added.

The researchers used a powerful new microscopy technique known as Cryo-EM (cryogenic electron microscopy) to cool samples of Fischerella thermalis and embed them in ice. Cryo-EM gathers thousands of images of sample particles in various orientations and uses computer algorithms to re-assemble the images into a detailed, three-dimensional composite, called a density map.

This method revealed some locations of chlorophyll f molecules present in Fischerella thermalis that are responsible for far-red light adaptation, Gisriel said.

As for future applications, the researchers said the work suggests several possibilities. Perhaps two crops could be grown together, such as tall corn with short alfalfa. Another outcome could be crops that thrive in a wider variety of weather conditions. There also may be applications for new generations of light-harvesting technology, such as photovoltaics.

This is fundamental research that paves the way, potentially, for other things, Gisriel said.

Visit link:
A science discovery made in the shade - Yale News

Baxter probe finds $276 million in overstated income – Mass Device

Baxter(NYSE:BAX) says its income for the past four years may have been overstated by $276 million.

The Deerfield, Ill.based healthcare products company said the figures came out of a previously announced internal probe into its foreign exchange trading practices. That investigation is now substantially complete, the company said in an SEC filing yesterday.

Baxter said its income was over-reported by $40 million for 2016, $117 million for 2017, $77 million for 2018 and $42 million for the first half of 2019. The company said it expects to file restated financial statements, its third- and fourth-quarter 2019 financial reports and its annual report by March 31, 2020.

The problem involved transactions using a foreign exchange rate convention historically applied by the company that was not in accordance with U.S. generally accepted accounting principles (GAAP). The company believes that the use of its previous exchange rate convention to generate non-operating foreign exchange gains and avoid losses had occurred for at least 10 years, Baxter said in yesterdays filing.

Yesterdays SEC filing is an important step forward in our internal investigation, the company said in a statement emailed to MassDevice.

Its important to note that these misstatements of foreign exchange gains and losses are non-operational in nature. This means they are unrelated to our core operations and business results. In fact, our preliminary 2019 results (announced January 11) reflect the fundamental strength of the business globally.

By the end of March, Baxter plans to announce our complete Q3 and Q4 2019 results and submit our restated financial results to the SEC. We take this matter very seriously and are focused on delivering these next milestones by the end of the quarter.

The Street appears to have already priced in Baxters income misstatements. BAX shares are only down slightly today.

This article has been updated with comments from Baxter.

Visit link:
Baxter probe finds $276 million in overstated income - Mass Device

How to verify that quantum chips are computing correctly – MIT News

In a step toward practical quantum computing, researchers from MIT, Google, and elsewhere have designed a system that can verify when quantum chips have accurately performed complex computations that classical computers cant.

Quantum chips perform computations using quantum bits, called qubits, that can represent the two states corresponding to classic binary bits a 0 or 1 or a quantum superposition of both states simultaneously. The unique superposition state can enable quantum computers to solve problems that are practically impossible for classical computers, potentially spurring breakthroughs in material design, drug discovery, and machine learning, among other applications.

Full-scale quantum computers will require millions of qubits, which isnt yet feasible. In the past few years, researchers have started developing Noisy Intermediate Scale Quantum (NISQ) chips, which contain around 50 to 100 qubits. Thats just enough to demonstrate quantum advantage, meaning the NISQ chip can solve certain algorithms that are intractable for classical computers. Verifying that the chips performed operations as expected, however, can be very inefficient. The chips outputs can look entirely random, so it takes a long time to simulate steps to determine if everything went according to plan.

In a paper published today in Nature Physics, the researchers describe a novel protocol to efficiently verify that an NISQ chip has performed all the right quantum operations. They validated their protocol on a notoriously difficult quantum problem running on custom quantum photonic chip.

As rapid advances in industry and academia bring us to the cusp of quantum machines that can outperform classical machines, the task of quantum verification becomes time critical, says first author Jacques Carolan, a postdoc in the Department of Electrical Engineering and Computer Science (EECS) and the Research Laboratory of Electronics (RLE). Our technique provides an important tool for verifying a broad class of quantum systems. Because if I invest billions of dollars to build a quantum chip, it sure better do something interesting.

Joining Carolan on the paper are researchers from EECS and RLE at MIT, as well from the Google Quantum AI Laboratory, Elenion Technologies, Lightmatter, and Zapata Computing.

Divide and conquer

The researchers work essentially traces an output quantum state generated by the quantum circuit back to a known input state. Doing so reveals which circuit operations were performed on the input to produce the output. Those operations should always match what researchers programmed. If not, the researchers can use the information to pinpoint where things went wrong on the chip.

At the core of the new protocol, called Variational Quantum Unsampling, lies a divide and conquer approach, Carolan says, that breaks the output quantum state into chunks. Instead of doing the whole thing in one shot, which takes a very long time, we do this unscrambling layer by layer. This allows us to break the problem up to tackle it in a more efficient way, Carolan says.

For this, the researchers took inspiration from neural networks which solve problems through many layers of computation to build a novel quantum neural network (QNN), where each layer represents a set of quantum operations.

To run the QNN, they used traditional silicon fabrication techniques to build a 2-by-5-millimeter NISQ chip with more than 170 control parameters tunable circuit components that make manipulating the photon path easier. Pairs of photons are generated at specific wavelengths from an external component and injected into the chip. The photons travel through the chips phase shifters which change the path of the photons interfering with each other. This produces a random quantum output state which represents what would happen during computation. The output is measured by an array of external photodetector sensors.

That output is sent to the QNN. The first layer uses complex optimization techniques to dig through the noisy output to pinpoint the signature of a single photon among all those scrambled together. Then, it unscrambles that single photon from the group to identify what circuit operations return it to its known input state. Those operations should match exactly the circuits specific design for the task. All subsequent layers do the same computation removing from the equation any previously unscrambled photons until all photons are unscrambled.

As an example, say the input state of qubits fed into the processor was all zeroes. The NISQ chip executes a bunch of operations on the qubits to generate a massive, seemingly randomly changing number as output. (An output number will constantly be changing as its in a quantum superposition.) The QNN selects chunks of that massive number. Then, layer by layer, it determines which operations revert each qubit back down to its input state of zero. If any operations are different from the original planned operations, then something has gone awry. Researchers can inspect any mismatches between the expected output to input states, and use that information to tweak the circuit design.

Boson unsampling

In experiments, the team successfully ran a popular computational task used to demonstrate quantum advantage, called boson sampling, which is usually performed on photonic chips. In this exercise, phase shifters and other optical components will manipulate and convert a set of input photons into a different quantum superposition of output photons. Ultimately, the task is to calculate the probability that a certain input state will match a certain output state. That will essentially be a sample from some probability distribution.

But its nearly impossible for classical computers to compute those samples, due to the unpredictable behavior of photons. Its been theorized that NISQ chips can compute them fairly quickly. Until now, however, theres been no way to verify that quickly and easily, because of the complexity involved with the NISQ operations and the task itself.

The very same properties which give these chips quantum computational power makes them nearly impossible to verify, Carolan says.

In experiments, the researchers were able to unsample two photons that had run through the boson sampling problem on their custom NISQ chip and in a fraction of time it would take traditional verification approaches.

This is an excellent paper that employs a nonlinear quantum neural network to learn the unknown unitary operation performed by a black box, says Stefano Pirandola, a professor of computer science who specializes in quantum technologies at the University of York. It is clear that this scheme could be very useful to verify the actual gates that are performed by a quantum circuit [for example] by a NISQ processor. From this point of view, the scheme serves as an important benchmarking tool for future quantum engineers. The idea was remarkably implemented on a photonic quantum chip.

While the method was designed for quantum verification purposes, it could also help capture useful physical properties, Carolan says. For instance, certain molecules when excited will vibrate, then emit photons based on these vibrations. By injecting these photons into a photonic chip, Carolan says, the unscrambling technique could be used to discover information about the quantum dynamics of those molecules to aid in bioengineering molecular design. It could also be used to unscramble photons carrying quantum information that have accumulated noise by passing through turbulent spaces or materials.

The dream is to apply this to interesting problems in the physical world, Carolan says.

Read the original post:
How to verify that quantum chips are computing correctly - MIT News

Indian Institute of Technology, Guwahati Recruitment 2020 – The Sentinel Assam

Indian Institute of Technology, Guwahati Recruitment 2020

Applications are invited for a Walk-in-interview for the following post(s) in the project entitled, Investigating the role of peroxisomes in Parkinson?s disease at the Department of Biosciences & Bioengineering, IIT Guwahati.

Post Name: JRF(GATE)

Posts: 1

Salary: 37210.00

Venue: Conference Room, BSBE

Date: 03 Feb 2020 (Monday)Time: 4 PM

Selection process: Candidates have to appear in the Walk-in-Interview along with an application/CV on plain paper giving details of all educational qualifications, experience, contact address, phone no., Email, etc. and submit photocopies of relevant documents at the time of interview on 03 Feb 2020 (Monday) at 4 PM. Venue: Conference Room, BSBE. Selection will be based on the performance of the candidate in the interview. Candidates will not be sent any call letters separately. An advance copy of the CV may be sent to the Principal Investigator.

Details: Click Here

Also Read: Assam University Recruitment Multiple Vacancy 2020

Excerpt from:
Indian Institute of Technology, Guwahati Recruitment 2020 - The Sentinel Assam

The number of cases of coronavirus in the world has exceeded 2 thousand persons – www.MICEtimes.asia

All 56 victims of the new virus died in China, but the number of cases has already exceeded 2 thousand persons around the world.

From a new type of coronavirus 2019-nCoV has already killed 56 people. This is with reference to the data published by the Chinese authorities, reports the Chronicle.info with reference to .net.

The data also suggest that all the deaths recorded in China, but more than 2 million people worldwide have been infected with the novel coronavirus.

President XI Jinping said during the Politburo meeting that China faced a serious situation, and health authorities worldwide are struggling to prevent a pandemic.

Recall that in 25 provinces of China declared the highest level of emergency response related to public health. The total population in these areas exceeds 1.2 billion people.

It is known that the virus has spread abroad, including to South Korea, Japan, Singapore, Thailand, Vietnam, USA, France and Australia.

Coronaviruses are genetically similar group of viruses that infect higher animals (mammals, birds, many reptiles), including humans.

In this family there are already six pathogenic for the human species: sometimes, this infection is asymptomatic, sometimes manifested in the form of a cold. In severe cases, the infection causes pneumonia, which can result in death of the patient.

Scientists have found that the new coronavirus 2019-nCoV is a kind of SARS virus (severe acute respiratory syndrome or SARS), which also emerged in China in 2002-2003 affected more than eight thousand people in 37 countries. Then killed 774 people. He was the seventh of the dangerous strain.

Coronaviruses have come to man from animals, presumably from bats. The likely focus of the spread 2019-nCoV is the seafood market in Wuhan, which is on the eve of the Chinese New year was full of wild animals: foxes, wolves, bats and even viverrini.

Most of the first hospitalized patients were somehow connected with the market of Wuhan. Scientists are not exactly revealed animals that are carriers of 2019-nCoV.

A group of Chinese scientists under the leadership Singana Lee from Wuhan University bioengineering has put forward his version of events: bats infected your coronavirus snakes, and their body two viruses exchanged their plots.

And about two years ago there was a hybrid virus 2019-nCoV, which by December 2019 reached out to people. Estimated owners researchers believe two snakes: the South China MNOGOPROFIL krayt and Chinese Cobra. In favor of this theory is the fact that both of them were sold at the Wuhan seafood market.

However, researchers from the Wuhan Institute of Virology has allocated the 2019 coronavirus-nCoV have a very sick patient and said that the closest structure to the coronaviruses of bats.

Also in the journal Nature has published an editorial with comments virologists from around the world. They all agree that snakes are unlikely to be the source of the coronavirus. Most experts shodyatsya the opinion that the virus came from a mammal.

In early January, Chinese scientists published in the database GenBank complete genome 2019-nCoV, to help doctors in other countries to identify the disease.

Under the microscope the virion coronaviruses appears as an oval with many small spines, obrazovannyh a special protein, which provides the fusion of the virus with the cell membrane of the attacked organism.

It is still unknown whether the virus is transmitted from person to person by airborne droplets. While the transmission is limited to family groups and health workers caring for the infected.

Michael Letko, and Vincent Munster of the U.S. National Institute of Allergy and infectious diseases found that 2019-nCoV, like its predecessor SARS enters the cage through the human ACE2 protein.

See the original post here:
The number of cases of coronavirus in the world has exceeded 2 thousand persons - http://www.MICEtimes.asia

Rats Learn to Drive Tiny Cars, Proving Rodent Neuroplasticity – The Great Courses Daily News

By Jonny Lupsha, News Writer

According to The University of Richmond website, the rats success in operating the vehicles depended in part on their environment. Rats housed in a complex, enriched environment (i.e., environment with interesting objects to interact with) learned the driving task, but rats housed in standard laboratory cages had problems learning the task, Professor Kelly Lambert said. This lends to the theory that enriching environments assist the brain in learning new tasks and behaviors. Neuroplasticitythe brains ability to learnseems to be far higher in rodents than once believed.

Neuroplasticity refers to how the brain learns, unlearns, and re-learns behaviors. Of course, there are behaviors we learn to how to do and there are functions of the brain that we do inherently, which are automatic.

We divide wiring functions of the human brain into three categories, said Dr. John Medina, Affiliate Professor of Bioengineering at the University of Washington School of Medicine.

The first category is called experience-independent wiring, he said. These neural circuits perform tasks like regulating our heartbeats and keeping our lungs working. Theyre called experience-independent because they dont need to be taught.

Second is experience-dependent circuitry. According to Dr. Medina, things that require learning, such as speaking a second language, are governed by our experience-dependent circuitry. They depend on experience to make their way into our grey matter.

The final category of how our brains are wired is called experience-expectant wiring, which is like a hybrid of the first two categories. Here, the brain is internally hardwired to expect some kind of external input, some kind of experience, Dr. Medina said. Then it finishes its hard-wiring. The clearest example of experience-expectant wiring is vision.

The visual system is not fully developed at birth. It requires photic exposureliterally light getting into the eyes after birthto finish wiring.

According to Dr. Medina, neuroscientist Don Hebb is responsible for our understanding of neurons in the brain and how the brain learns behaviors, unlearns them, and also re-learns behaviors in place of earlier learned behaviors.

He said that when two neurons synaptically connected to each other fire repeatedly, molecular alterations occur in both, Dr. Medina said. As a result, their relationship strengthens. The two are now electrically connected more strongly than they were before the repetitions happened.

However, this can happen between more than two neurons, leading to an entire cluster of neurons that fire together to initiate a thought or behavior pattern. Conversely, when two neurons fail to ignite together, the connection between them dies off and we unlearn a behavior or thought.

Taking this example to its logical conclusion, the connections between our neurons can change over time and we can learn new behaviors to replace old ones. If youve only met someone once and have forgotten their name, but you see them regularly, you may associate their face with what you think their name is. The neuron associated with their face may fire with the neuron associated with that name.

However, if you call them that name and they correct you, those two neurons wont fire together as much anymore. Instead, the neuron that holds their face in your memory may fire together with a new neuronthat of their actual name. This happens all the time as we adapt to new behaviors. We unlearn one thing and replace it with another in a kind of subconscious trial and error.

And if youre a rat behind the wheel of an automobile, your neurons may be wiring, firing, and rewiring like fireworks on the Fourth of July.

Dr. John J. Medina contributed to this article. Dr. Medina is an Affiliate Professor of Bioengineering at the University of Washington School of Medicine. He holds a Ph.D. in Molecular Biology from Washington State University. In 2004, he was appointed to the rank of Affiliated Scholar at the National Academy of Engineering.

Go here to see the original:
Rats Learn to Drive Tiny Cars, Proving Rodent Neuroplasticity - The Great Courses Daily News

It’s go-time: a doctor and student engineers work to make catheterization easier – Scope

As a clinical mentor for the Bioengineering Senior Capstone Design course, Stanford urologist Craig Comiter, MD's first job was to write a story about a problem he had observed in his practice. Students in the course, all senior undergraduate bioengineering majors, would read several such vignettes, choose an unmet need within one of them, and then work in teams to develop a solution.

Comiter wrote about something he saw all the time; the strugglesof patients who have to self-catheterize in order to urinate because of abrain, spinal cord, or nerve problem. His scenario described a young woman whowas paralyzed from the waist down. He detailed the arduous process she had toperform multiple times each day to empty her bladder, and included the frequenturinary tract infections (UTI's) she contracted as a result.

Students Maria Iglesias, Amanda Urke, Gabe Ho, and Issac Justice all chose Comiter's scenario. "We were drawn to the idea of wanting to improve the patient's quality of life," said Iglesias. "While we personally couldn't really understand what she was going through, we recognized that our lives would be very different if we had this amount of difficulty with a simple task that we take for granted."

To help them understand the patient's perspective, the team created a survey that asked patients to rate the difficulty of each step of the procedure. The results made it clear that the procedure was hardest for women, especially those with impaired mobility. Steps included finding a private place, transferring out of the wheelchair, removing clothing, cleaning the vaginal area, inserting a catheter into the urethra, and then reversing the process. For all women, the single biggest problem was locating the opening of urethra, which often requires the patient to strap a mirror onto her leg.

"Not only does this prevent some women from being able toself-catheterize, it's also one of the major reasons females get UTIs," saidComiter. "They miss the urethra and contact the vagina, contaminating thecatheter."

"The responses made us think about how, through the mechanism of use, we could help the patient be certain they were on target," said Urke. She added, "It also brought home the importance of conducting surveys and actually speaking to patients before you get into the design of a solution."

Based on this understanding, the team decided that the most intuitive approach for women would be to use the vagina as an anatomical landmark to help locate the urethra. With input from Comiter and course co-instructor Richard Fan, PhD, they developed more than 40 prototypes of a small plastic device with a handle, a vaginal insert, and a guide that holds the catheter.When the user holds the device with the insert just inside the vagina, the catheter guide is lined up at the urethral opening, and the patient is able to slide the catheter into place.

Next the team created a pair of shorts with a faux vagina and urethra and used it to test most promising prototypes on themselves and on volunteers, even performing the procedure blindfolded. By the end of the spring quarter, they had a working prototype -- the Cath Path.

They entered an NIH-sponsored biomedical engineering competition and won a top prize, prompting them to think seriously about taking their solution forward into patient care. They are currently exploring regulatory pathways and planning next steps including usability testing with real patients.

"It's a device that could help many people," said Comiter. "While self-catheterization is still a complex process for women, this simple, low-cost approach can save time, make a frustrating process easier, and decrease the risk of infection."

The experience showcased the benefits of interdisciplinary collaboration, he said:

When doctors think infection, our solution is antibiotics. When these engineering students heard about infection, their response was, 'Let's find a way to prevent the contamination of the catheter in the first place.' I was the mentor here, but I think I learned as much as the students did. Working with them made me a better problem-solver.

Photo of the team at Biodesign's Health Technology Showcase by Stacey McCutcheon

Link:
It's go-time: a doctor and student engineers work to make catheterization easier - Scope

From space tourism to robo-surgeries: Investors are betting on the future like there’s no tomorrow – Financial Post

It may be difficult to envision, but there is a potential future be it 10, 20 or even 30 years down the line where humans are able to plan a cozy vacation into space, blast by a series of satellites that now provide them with Internet access and have their most serious illnesses treated by allowing bioengineers to alter their DNA.

Its one possible future that proactive investors, even those in typically reactive institutional settings, have begun to place large and risky bets on becoming a reality.

In April, the Ontario Teachers Pension Plan created a new department called the Teachers Innovation Platform that has a mandate to invest in disruptive tech and made its first big splash in June by backing Elon Musks SpaceX. The pension plan has particular interest in the companys Starlink project, one that aims to fire more than 11,000 satellites into low orbit, interlink them all and have them act as a new provider of Internet connectivity.

For investing ... you want to look 15 to 20 years down the line and say: 'Is this still going to be impacting peoples' lives?

The Canada Pension Plan Investment Board has put a similar emphasis on investing in disruptive technology, announcing in late 2018 that it had made a private investment in Zoox, a California-based company that aims to operate a fleet of robo-taxis. Only months ago, the pension plan bought US$162 million worth of Skyworks Solutions Inc., a semiconductor firm creating chips that will allow the next wave of phones to work in 5G networks.

As for retail investors, theyve likely never had as many options to hedge their portfolio toward the future. The 2019 IPO market offered them even more, bringing a basket of futuristic options to the market, including Beyond Meat Inc., a producer of plant-based meat, and Virgin Galactic Holdings Inc., the latest brainchild of Richard Branson, which is developing spacecraft that may allow for the development of a space tourism sector.

But the investors buying these stocks arent buying them with the hope that theyll hit their peak in 2020.

You have to recognize the world is changing, said Hans Albrecht, the portfolio manager for Horizons ETFs Industry 4.0 fund. Theres nothing wrong in investing in Pokemon cards if theyre hot now or whatever the latest trend may be, but thats a trade. For investing you want to look 15 to 20 years down the line and say: Is this still going to be impacting peoples lives?

It wont be long, Albrecht suspects, before his coffee maker is able to receive signals from his mug that tell it to begin brewing a new serving once hes three-quarters of the way through his first cup in the morning.

If that scenario sounds too futuristic, its one that only scratches the surface, he said. When hes running low on espresso packages, a chip in his pantry keeping track of stock may be able to automatically order more from Amazon, which at that point, may have implemented one-hour shipping, to ensure hell never run out.

Thousands of consumers already have access to smart home technology through Google Home or Amazon.com Inc.s Alexa, which allow for the linking of devices such as thermostats, lights and televisions. Its advancements in artificial intelligence and edge computing, which will effectively replace the cloud and allow for individual items in a home to process data, that will bring this technology into the future.

Figuring out how to play technology like edge computing which may very well become mainstream in a decade isnt exactly simple.

Investors will have two options: they can bet on the end point user of the technology in Albrechts coffee scenario, that would mean investing in the company that produces the coffee maker or they can look to the firms that are developing the components that power it.

Albrecht leans towards the latter, suggesting that there would be far too much competition among the end point companies while there would only be a handful of leaders on the components side. A company like Analog Devices Inc., may play a central role in the implementation of that technology because its building everything from the sensors and their networks to processors.

Investors may be able to apply similar logic with 5G, according to CIBC World Markets tech strategist Todd Coupland.

Consumers will likely only begin to see the wide rollout of 5G, which would enable devices to operate at speeds that as much as 100 times faster than the current 4G tech, in 2020. That means that it might be a bit early to invest in device producers such as Apple Inc. or Samsung Electronics Co Ltd. for that exposure. Instead, Coupland suggested investors eye a company like Keysight Technologies Inc., which builds the equipment that carriers have been using to test out their services ahead of launch.

Goldman Sachs expects 50 million to 120 million 5G devices to be active in 2020 and if that should be the case, components manufacturers in Qualcomm Inc. and Marvell Technology Group Ltd. may warrant attention as would providers such as Nokia Ovj, which already has 50 deals in place to install its radio access equipment, AirScale, around the world. The equipment supports multiple frequencies and allows for a quick transition over to 5G.

That list doesnt include the Canadian telcos and for good reason.

In Canada, Rogers and Bell, their attitude is: See how it goes in the U.S. and well be at least one year behind, Coupland said.

5Gs full potential likely wont be reached for a decade, he said, and the futuristic possibilities it opens up will likely only be reached in the second half. When combined with the power of quantum computing, managing a fleet of self-driving cars and, who knows, removing traffic lights from the streets becomes a possibility, according to Christian Weedbrook, the CEO of Toronto-based quantum computing company Xanadu.

Weedbrooks company has gained the attention of Georgian Partners, a private-sector venture capital firm that has invested hundreds of millions of dollars in upstart Canadian tech companies.

What makes quantum computing, a draw for Jason Brenier, Georgians vice-president of strategy, is its ability to solve previously unsolvable problems.

Weedbrook imagines a future where quantum computers control hundreds of autonomous vehicles for Uber Inc. or Lyft Inc. and provide each individual car with the fastest route to its destination, analyzing traffic, time a trip perfectly so that red lights can be mostly or completely avoided, and in the case of a pool scenario, figure out how to do that with multiple stops.

Investing in early stage technology comes with its challenges. Because Georgian focuses on private investments, there is no stock performance to point to and not much in the way of fundamentals to rely on.

Many of these tech companies that are seeking funding from the firm may show promise but wont pan out in the future. Brenier knows this and says thats one of the reasons why Georgian has its own scientists on staff.

Instead of making blind bets on the future, Georgian turns to its applied research and development team to identify new opportunities based on new academic research and to even conduct their own in order to determine whether a new idea is actually viable.

That gives us some unique insight into how some of these things are taking off, how practical they are from an investment perspective and determining the timing of some of them, Brenier said.

The Georgian team is futurist, but theres still a limit on how far in advance they want to support a new wave of tech. We dont want to work on things that take 20 years to make a breakthrough, Brenier said.

Where breakthroughs may be even more rare for futurist investors, but the potential returns all the sweeter is in health care. The possibilities here, especially when tech plays a part of the equation, appear to be boundless.

Albrecht sees the potential in robots being able to perform surgery on humans. The portfolio manager highlighted Intuitive Surgical Inc. and its da Vinci Surgical System as an example of how this is already occurring. Through a console that offers them a 3D view of the surface area theyll be operating on, surgeons can use controllers to perform procedure with four robotic arms that offer a greater range of motion than human limbs.

Intuitive doesnt just sell the machines, it sells the accessories such as scalpels that are replaceable and need to be repeatedly ordered. So the more da Vinci units it sells, the more it opens itself up for further gains to its bottom line through accessory sales.

The next step, Albrecht said, is for this technology to allow surgeons to perform surgeries around the world remotely. After thats accomplished, humans may be removed from the equation altogether with AI.

You take the smartest doctors in the world and they might just have the slightest tremor in their hand and might not get it perfect, but a machine will come as close to that as possible, he said.

Health care now makes up about a quarter of the CIBC Global Technology Fund, which is co-managed by Michal Marszal, who has a particular interest in gene therapy.

The technology may still be in development, but Marszal said scientists will soon be able to treat certain conditions, specifically those that plague humans as a result of mutated genes, by biologically engineering new sequences to replace them.

Take haemophilia, a condition that reduces the ability of a persons blood to clot. Treating haemophilia A, which is caused due to a deficiency of a protein called factor VII, may soon be possible by removing cells from the patient, biologically engineering gene sequences with the protein in them and reinserting them.

Gilead Sciences Inc., a company that is in Marszals mutual fund, is working on gene therapy that might even be able to fight cancer. According to Marszal, the process involves removing immune cells from a human body and genetically modifying them so that they become supercharged and are better positioned to fight cancer.

The returns on investment in successful therapies are extremely high, Marszal said. Thats really the next decade or 25 years in medicine.

Thinking that far ahead may be difficult for the average investor, who is often concerned with year-end returns. But it might be worth stopping as some futurists do, even during a quiet moment like a morning coffee, to consider just how different the world will look in a decade and perhaps selfishly, how theres profit to be made from it.

Email: vferreira@nationalpost.com | Twitter:

Continue reading here:
From space tourism to robo-surgeries: Investors are betting on the future like there's no tomorrow - Financial Post

Edited Transcript of XVIVO.ST earnings conference call or presentation 24-Oct-19 12:00pm GMT – Yahoo Finance

GOTEBORG Oct 25, 2019 (Thomson StreetEvents) -- Edited Transcript of Xvivo Perfusion AB earnings conference call or presentation Thursday, October 24, 2019 at 12:00:00pm GMT

Ladies and gentlemen, welcome to the XVIVO Perfusion Third Quarter 2019 Report Webcast. Today, I am pleased to present Magnus Nilsson, CEO; and Christoffer Rosenblad, CFO.

I will now hand you over to Magnus Nilsson. Sir, please go ahead.

Thank you, and welcome to the 28th quarterly report of an independent XVIVO Perfusion. And this is, as we said, the interim report for the third quarter.

Next slide, please. So the highlights. It's been an important quarter for us, and I'll try to put you into the picture.

Q3, first time, rolling 12 months nondurable sales over SEK 200 million. We have received a patent approval for the Perfadex Plus, and we have started a very interesting collaboration to develop fast diagnostic tests using biomarkers at -- to be used in EVLP and similar.

And repeating for the full year, the most important highlights is, of course, the PMA for XPS and STEEN Solution, the patents for the heart preservation fluids. The positive results of the clinical safety studies in Lund on the heart device and the deepening -- deepened collaboration or cooperation with Lung Bioengineering.

So next slide, please. So the sales highlights for the quarter was that we sold the second XPS to China, which is really interesting market. I'll come back to that. We -- also Lung Bioengineering has acquired their second XPS when they opened their new EVLP center, and we have a continued stable gross margin during growth for the quarter and for the year. We can see for the year continued strong sales all over the year, nondurable goods, 25% in Q3. Warm nondurable growth rolling -- is rolling on a 40% level year-to-year. And we see also continuation of the positive sales trend for cold preservation, which is an indication that the global market for transplantation is growing also outside that main markets.

Next slide, please. So some more numbers here. The profit and loss statement to be highlighted is, of course, the net sales, but then the -- again, the stable gross margin of nondurable goods. That's the important gross margin, of course. And we are running on a level pretty similar level on the selling expenses. We built up continuously our sales force, which is more of a customer support. That is technical advisers being out on the clinics, helping them to perform EVLP.

We can also see that we are a little bit higher R&D. Same thing here. We developed our clinical teams since we are in a situation where we start up a number of clinical studies. And then that we're still doing all this intensive investment in R&D and built up our organization still can keep a very good profit level -- counted on the EBITDA level. There is one item affecting comparison. And that is, of course, as I said before, that we have mirrored bonus program for the employees outside Sweden, which is based on the share price, mirroring the Swedish warrant program.

Next slide, please. So we are in an intensive phase of the company, where we strengthen ourselves in hiring new competencies and capacities, such as our first transplant surgeons and other clinical trial experts. So the buildup of the heart and PrimECC teams that will run the multicenter studies over the world, and we're also extending the team supporting the Lung EVLP market development.

Next slide, please. So a few words about the Chinese transplant market. It is a very fast-growing market, a lot of activities. I think more than 10 new centers have been certified to do transplants in China. It's growing from relatively low level But with a very high speed, and it has been about a 50% increase during the last years and we -- something like that probably this year as well. So therefore, it's very encouraging that we now have placed our second or sold our second EVLP in China to the second largest transplant clinic in China, the -- one of the major hospitals in Beijing. And this clinic makes about 100 -- over 100 transplant last year. And you can -- necessity they are increasing very rapidly, and they're just being trained actually these days. We -- just yesterday, I got a report that the training was -- the first training practice run was performed in Beijing. So this continues to be one of the more exciting markets where we focus on, and we'll focus on in the future.

Then another thing, the important product for us, obviously, is Perfadex. And as you know, we have a upgraded ready-to-use product that -- so that -- which is more convenient and safe for the patients. You don't have to mix at site. It's now been patented in Europe, which is very encouraging. And we have submitted patent applications in all important markets.

Next slide, please, #8. XVIVO and MyCartis collaboration. MyCartis is a company specialized in developing fast analysis tools and assays, so we will -- we are now part in a collaboration, where we will -- they will help us on developing these assays, which can be used and generate results within 20 minutes at bedside, so to speak, on the EVLP, which is thought to be very important in assessing and identifying how good lungs and other organs are after XVIVO perfusion. So these biomarkers and this fast evaluation of biomarkers has a potential to increase the number of EVLP and also increase the, obviously, the chances of positive outcomes for the patients.

Next slide. We continue to cooperate with Lung Bioengineering, as I said. And they -- and not only with Bioengineering. Actually with another entities in United Therapeutics. So they have opened now their second EVLP center in Jacksonville, Florida, in addition to their center in Maryland. And we collaborate both -- we're helping them to set up using the XPS EVLP process and also are cooperating in marketing of these services on centers so that the centers can choose to either use EVLP, if they have an EVLP system themselves; or if they want to use these services, which uses our products, but at the United therapeutics or Lung Bioengineering sites. We also have started collaborating with them in their research on the xenotransplantation.

Next slide, please. So this part is about the R&D pipeline, which we drive with high speed and a lot of focus to ensure future growth and to employ the technology and the experience we've had drawn on lungs into other organs.

So the investment in future EVP (sic) [EVLP] growth. So this is about developing the EVLP or the lung indication to use it more in order to get more organs available to the patients. So we developed the XPS technology with new sensors, and we also then again want to develop markers to use -- to be used in conjunction with the running of the XPS.

We're also looking at the clinical development, in expanded use of donation after circulatory death. That is the usual DCD lungs. And also for anti-infection therapy, we can -- we see now one of the results of that support is the recent publication on virus risk hepatitis C reduction during EVLP. And we also developed further the EVLP protocol for the ventilation strategy; organ proning, which is to turning it to get perfusion on all sides, et cetera. So a lot of development going on in order to make the EVLP even better in determining which organs that can be used. We also investigate the immunological response to EVLP, targeting both short-term organ function and long-term survival.

Next slide. So if you look at employing this technology on new organs. We have, of course, our #1 priority, the heart transplant project, which is about optimizing preservation to prolong the time outside the body, because we know that a heart is very demanding in the sense it can only survive 4 to 5 hours outside the body today. And we have the aim to keep the organ in better shape during the process and, therefore, both being able to use older donors and also to extend the time outside the body to be able to use organs from further away than today.

The #2 priority is the PrimECC. It's about an optimized solution. So it's based on our knowledge and technology around Perfadex and STEEN Solution to have an optimized priming solution to reduce the known side effects.

And as a third priority and a lower priority, but still very interesting is to see how we can employ the STEEN Solution technology on the liver and kidney transplants. We have been supporting that for a time coming -- for a time where in clinical studies, STEEN Solution with some additives has been used, both in liver and in kidneys today clinically. The fourth priority, which is a relatively low priority, but may be interesting in the longer-term future is perfusion of the isolated organs and tissues.

Next slide, please. So again the heart transplantation. It's a heart perfusion and preservation solution and device developed by Professor Steen originally. And that first device prototype has been used in a number of preclinical trials, where he's shown -- showed that this non-oxygenated time, called NIHP, results in a better organ quality. So the idea is to keep the organ resting, but profused with this new solution in a low temperature, reducing the metabolism, which then facilitates a longer preservation time. And it's shown up to 24 hours in pigs in publications and even longer.

It's also being used in xenotransplantation from pig to monkey. And using that device, they were able to increase the survival up to 6 months. This was never been done before. That was published in Nature in December of last year. And after that, the technology has been employed in Lund University Hospital in a safety clinical trial. The first 6 patients were evaluated after 6 months and partly public -- publicized, where they can said that the heart can be safely preserved with this NIHP technology, resulting in successful transplantations and the reduced risk of ischemic induced reperfusion injury. More patients have been included with this, and the study is ongoing in parallel to all other activities.

Next slide please, 14. So we've been working very hard now with a number of activities, especially the clinical team build up, ramp-up of machine, disposable and solution production. And we see a huge interest in worldwide and the clinical participation in the clinical trials, both in Europe, U.S. and Australia. And on preparations for all these 3 are ongoing and Europe, obviously, first. We have several authorities that have cleared this, but we will -- we're looking to have all centers -- all regulatory authorities, all centers clearing the protocol before we start the inclusion. This moves on very well. And of course, the important is not the first patient in. The important is the last patient out, so that means that we need to have all the centers up and running. That's the most important, and that's what we're focusing on.

Next slide, please. PrimECC. So PrimECC background, just for those who have not heard it. Priming solutions are used in all runs of heart-lung machines, and they're primed before they can -- you start using them in the patient. And that means that about 1.5 liter of blood of the patient comes into the circuit of the heart-lung machine and that 1.5 liter of priming solution goes into the patient. That has -- of the solution used today, there is a number of known side effects of the solutions used today. About 600,000 to 700,000 of these operations are done worldwide each year. And the whole idea now is that the PrimECC has been developed to alleviate these side effects. That's the whole idea of this project. And we have done quite a bit so far.

And next slide please, 16. So it's a patent in all major markets, it's CE marked. We have done a clinical study of 40 plus 40 patients, which show that PrimECC is safe to use. It also show that we can improve fluid balance, reduction of side effects using the heart-lung machines primed with PrimECC.

So what we do right now is to scale up both the production. We had to change the bag for regulatory reasons to eco-friendly bag, and we've done all that validation of production. We have submitted that -- all that technical file to the notified body, which are looking at the file. And as soon as they are done, we can then start up the clinical trial. We have meanwhile also built up the clinical and regulatory team around the product, PrimECC product, which will run than the clinical trial and the regulatory implications.

So the whole idea here is to make a few, 1 or 2 studies, to get more clinical documentation showing then and developing the effects of this in reducing the side effects. It's a high interest from the clinics to participate in these studies.

Next slide, please. So we look forward. We continue to focus on the thoracic transplantation. That's primary focus. It's lungs, obviously, further to support the EVLP technology and clinical practice of using it; the heart preparation for multicenter studies in all major markets, that's U.S., Europe and Australia; and also -- and PrimECC preparation for the multicenter study, waiting for the regulatory authorities' go ahead.

We are looking at the abdominal transplantation, a new indication. It's a secondary focus, but we feel it's very interesting to see how we can use the technology and the experience further into organs in abdominal organs like liver and kidney. And we have been supporting with good results the clinical trials using STEEN Solution in these organs, and we further investigate how to employ the technology further and see how we can create value of what we've done in lungs and the hearts to this important and interesting indications.

So the long-term goals: Solidify the position in thoracic surgery. And then build new business using the STEEN Solution technology in liver and kidney. That's long term goal.

And we are open for questions, please.

================================================================================

Questions and Answers

--------------------------------------------------------------------------------

Operator [1]

--------------------------------------------------------------------------------

(Operator Instructions) Our first question comes from the line of Daniel Albin from Danske Bank.

--------------------------------------------------------------------------------

Daniel Albin, Danske Bank Markets Equity Research - Research Analyst [2]

--------------------------------------------------------------------------------

Can you hear me, guys?

--------------------------------------------------------------------------------

Magnus Nilsson, Xvivo Perfusion AB (publ) - CEO & MD [3]

--------------------------------------------------------------------------------

Yes.

--------------------------------------------------------------------------------

Daniel Albin, Danske Bank Markets Equity Research - Research Analyst [4]

--------------------------------------------------------------------------------

Yes. Good. Okay. So I have a couple of questions. My first question is maybe a bit more of a technicality, but looking at the sales of cold preservation, this quarter seems to be a pretty good one. I'm just wondering if you could elaborate a bit more on the reasons behind this strength. And how we should view the growth rates going forward? You're mentioning that the global market is growing. Is it growing more than the 6% last few years? Or how should we view this?

--------------------------------------------------------------------------------

Magnus Nilsson, Xvivo Perfusion AB (publ) - CEO & MD [5]

--------------------------------------------------------------------------------

I think it's mirroring a worldwide growth of lung transplantation as such. I don't think we should pay too much attention to a single quarter. We will see in the long-term trend if that will continue. We know that more -- we're seeing more countries buy and clinics buying also in South America and so forth, but we don't really know if that will increase over the kind of long-term trend of 6% to 7%. It's too early to say.

--------------------------------------------------------------------------------

Daniel Albin, Danske Bank Markets Equity Research - Research Analyst [6]

--------------------------------------------------------------------------------

Okay, yes. And my second question then. So you're mentioning China here growing very fast, and I'm wondering if you could give us maybe some bit more clarity on the regulatory pathway required by the FDA or the MPA nowadays regarding your products and then Perfadex and also the EVLP solution. What are the lead times that required clinical studies you're obligated to do, et cetera?

--------------------------------------------------------------------------------

Magnus Nilsson, Xvivo Perfusion AB (publ) - CEO & MD [7]

--------------------------------------------------------------------------------

So normally, it's -- traditionally or historically, it takes about 2 years to get product registered in China if you have the right documentation. We already STEEN Solution. We have several of the disposables already approved in China. We have -- the things missing so far is the XPS. However, it's okay to use the XPS in -- as an exception still in -- since transplantation -- lung transplantation is very young there, they allow them to use them anyways.

But we are in the -- rather late -- should be in the rather late stage of having XPS approved. And obviously hard to say, but we -- I would imagine that within -- in the next 6 to 9 months, we should have a registration of XPS in China. We have Perfadex as before registered.

--------------------------------------------------------------------------------

Daniel Albin, Danske Bank Markets Equity Research - Research Analyst [8]

--------------------------------------------------------------------------------

Okay. And how do you view then the, I guess, the ramp-up of EVLP procedures in China?

--------------------------------------------------------------------------------

Magnus Nilsson, Xvivo Perfusion AB (publ) - CEO & MD [9]

--------------------------------------------------------------------------------

It's obviously early stage. But again, we see how quickly it grows. What they have problems with in China is that they are not used to good ways of taking care of the donor. So the donor management is rather, let me say, not too developed, which means that the lungs or the organs they receive vary in quality quite a bit, and that's what they have -- they said that to us that for that reason, they think EVLP is very important for them in order to check if the organs are okay since again, the variation, I should say, of the organ quality is pretty large. So they believe that EVLP will be an important addition to their clinical practice, although we have to say that this is, again, transplantation -- lung transplantation is very new, and obviously, this technology is for them, totally new.

On the other hand, I have experienced from other product -- taking out the products to China, and they always want to start with the most advanced. They never go for the simple solution. So from my time in Vitrolife, I know that once the Chinese start up, they want to go for the cutting-edge technology, and I think that's why they have been so interested in taking on this EVLP. But we will probably have to wait a little bit longer probably -- maybe a year or so until we see a significant increase in EVLPs there. But I have no doubt that China will be a very important market for us just in the next 2 to 3 years.

--------------------------------------------------------------------------------

Operator [10]

--------------------------------------------------------------------------------

(Operator Instructions) Our next question comes from the line of Arvid Necander from Redeye.

--------------------------------------------------------------------------------

Arvid Necander, Redeye AB, Research Division - Analyst [11]

--------------------------------------------------------------------------------

Okay. So my first question relates to the collaboration with United Therapeutics. So when we saw the delivery of the first machine, we saw quite a big uptick in the sales growth related to warm perfusion. How correlated was this? And do you expect to see a similar impact now that the second machine is delivered?

--------------------------------------------------------------------------------

Magnus Nilsson, Xvivo Perfusion AB (publ) - CEO & MD [12]

--------------------------------------------------------------------------------

Yes. It's a tough question because I try to predict what other people do, but we know that they're very dedicated in providing this service to the U.S. clinics. They are very dedicated. They put a lot of money into having the service in order to have more transplant available. I know their CEO is very -- is very dedicated in advancing this technology in order to get more patients, transplantation -- transplanted.

So I can only judge from what I see in terms of how many -- how much resources they put in. And what kind of big focus they have. So I'm convinced that over the years, they will increase significantly the number of -- or percentage of EVLPs done by their service compared to the overall number. And for us, it's very good because I think that a lot of clinics are not big enough to -- can employ this technology by themselves, and that I foresee more or less that in the next year or so, we will see a pretty rapid increase in this service. I would be surprised otherwise.

We have already been starting co-marketing with them, helping or going traveling with them to clinics and to explain the difference and the similarities for the clinics using this service versus using our technology. So I can just say that they're very determined and put a lot of resources into it, which I think is very encouraging.

--------------------------------------------------------------------------------

Arvid Necander, Redeye AB, Research Division - Analyst [13]

--------------------------------------------------------------------------------

Okay. And also, if you could just address the recruitments you've made a bit more. How do you see the headcount increasing going forward? Are we -- should we expect to see the same trend? Or do you see a bit of a slowdown now going forward?

--------------------------------------------------------------------------------

Magnus Nilsson, Xvivo Perfusion AB (publ) - CEO & MD [14]

--------------------------------------------------------------------------------

Yes. So what we've done -- we can say that we have kind of a pretty steady growth when it comes to marketing. It's no explosion there. It's an add-on every now and then when we -- in more or less parallel with the sales increase. What we've done is to built our development team. So to run these huge clinical trials for us, several -- I mean, heart will be on all continents. We had to build more competence and teams in the heart transplantation field and also, to some extent, on the PrimECC thing.

So this will continue for some quarters more to complete the buildup of those clinical teams. After that, I foresee that we go back to a more gradual increase again. So maybe a couple of quarters where we complete the kind of recruitment of these clinical teams. After that, I see more -- going back to a more gradual growth in terms -- in parallel, more or less how we place up new machines and so forth.

--------------------------------------------------------------------------------

Arvid Necander, Redeye AB, Research Division - Analyst [15]

--------------------------------------------------------------------------------

Okay. Yes, right. And then just a last question. I guess I popped out related to the subject that you talked about before. Related to China, how do you see the reimbursement path? Of course, very hard to speculate, but what's your sense? And if you have any take on that going forward?

--------------------------------------------------------------------------------

The rest is here:
Edited Transcript of XVIVO.ST earnings conference call or presentation 24-Oct-19 12:00pm GMT - Yahoo Finance

Ottawa-based treatment a leap forward in addressing heart failure – Edmonton Sun

It took years for Emilio Alarcon and his University of Ottawa Heart Institute research team to fully believe what they were seeing that a gel they had developed containing human collagen was repairing damaged hearts in mice.

They repeated their research study several times, coming up with randomized, blinded results, just to make sure the findings were correct.

We had to complete it many times because we couldnt believe it, he said.

The results of that work, five years in the making, were published in the prestigious journal Nature Communications on Friday. Alarcon and Erik Suuronen, a scientist in the division of cardiac surgery and director of its biomaterials and regeneration program, are lead authors.

The injectable material is the first in the world prepared using human collagen and is being called an unprecedented leap forward in addressing repair of cardiac muscle after a heart attack.

The work is still years away from clinical use on humans, but the findings are expected to attract attention because of the potential of the gel, which is designed to be injected into the hearts of patients with damaged heart tissue after a heart attack.

Alarcon said his team believes it performs better than any of the cell-based therapies or drug treatments currently available. The treatment works, he said, by increasing the number of cardiac muscle cells and blood capillaries in the tissue around damaged areas of the heart. The gel also helps bring more wound-healing cells to the site to promote repair.

Heart diseases are the leading cause of death around the world, and coronary artery disease, which can lead to a heart attack, is the most common.

About 10 per cent of people who have a heart attack (or myocardial infarction) will develop scarring and thickening of the heart wall that can lead to heart failure, which has a high mortality rate and its treatment is costly to the health system.

Alarcon noted that patients in remote areas without easy access to health care and those who dont seek immediate treatment or dont know they had a heart attack are more likely to suffer heart muscle damage. The treatment being developed by the heart institute team restored heart function in mice with scarred cardiac muscle.

The heart institutes BioEngineering and Therapeutic Solutions (BEaTS) team are hopeful their human collagen gel will one day lead to a recovery of heart function and prevent heart failure in humans, said Alarcon, but more testing is required.

The study published Friday is a first step toward that potential treatment, he said.

In Canada, approximately 600,000 patients live with advanced heart failure and health-care costs amount to more than $2.8 billion every year. As people live longer, both the number of patients and the cost of treatments are likely to increase.

ALSO IN THE NEWS

Mistake airline fares are the best way to score super cheap plane tickets. Heres how

Canadian scientists say they have produced the rarest drug on earth for cancer treatment

Fourth federal government office building treated for bedbugs

See the original post:
Ottawa-based treatment a leap forward in addressing heart failure - Edmonton Sun